Hepatocellular carcinomas 2-3 cm in diameter: Transarterial chemoembolization plus radiofrequency ablation vs. radiofrequency ablation alone

University of Ulsan, Urusan, Ulsan, South Korea
European journal of radiology (Impact Factor: 2.37). 02/2011; 81(3):e189-93. DOI: 10.1016/j.ejrad.2011.01.122
Source: PubMed


There is debate whether transarterial chemoembolization (TACE) plus radiofrequency ablation (RFA) is more effective than RFA alone in the treatment of patients with small hepatocellular carcinoma (HCC). We therefore retrospectively compared these treatments in patients with HCCs of diameter 2-3 cm.
Outcomes, including tumor progression, survival rates, and major complications, were compared in 83 patients (83 tumors) treated with combined TACE and RFA and in 231 patients (231 tumors) treated with RFA alone.
Median follow-up periods were similar in the TACE+RFA and RFA alone groups (37 vs. 38 months). During follow-up, local tumor progression was observed in 16% and 41% of tumors, respectively. The 1, 3, and 5 year local tumor progression-free survival rates were significantly higher in the TACE+RFA group (95%, 86%, and 83%, respectively) than in the RFA-alone group (78%, 61%, and 53%, respectively; P<0.001). The 1, 3, and 5 year overall survival rates, however, were similar in the TACE+RFA (93%, 72%, and 63%, respectively) and RFA (93%, 73%, and 53%, respectively) groups (P=0.545), as were the rates of major complications (1.2% vs. 0.4%).
Combined TACE and RFA was safe and provided better local tumor control than RFA alone in the treatment of 2- to 3-cm sized HCCs, although survival rates were similar.

Download full-text


Available from: Jin Hyoung Kim, Jun 19, 2014
  • Source
    • "Regarding small HCCs less than 3 cm, RFA alone is similarly effective to the combined therapy (2). However, the combined therapy may be necessary to more effectively block local tumor progression in patients with HCC ranging from 2 cm to 3 cm in size (18). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To compare the effectiveness of radiofrequency ablation (RFA) combined with transcatheter arterial chemoembolization (TACE) with surgical resection in patients with a single hepatocellular carcinoma (HCC) ranging from 2 to 5 cm. The study participants were enrolled over a period of 29 months and were comprised of 37 patients in a combined therapy group and 47 patients in a surgical resection group. RFA was performed the day after TACE, and surgical resection was performed by open laparotomy. The two groups were compared with respect to the length of hospital stay, rates of major complication, and rates of recurrence-free and overall survival. Major complications occurred more frequently in the surgical resection group (14.9%) than in the combined therapy group (2.7%). However, there was no statistical significance (p = 0.059). The rates of recurrence-free survival at 1, 2, 3 and 4 years were similar between the combined therapy group (89.2%, 75.2%, 69.4% and 69.4%, respectively) and the surgical resection group (81.8%, 68.5%, 68.5% and 65%, respectively) (p = 0.7962, log-rank test). The overall survival rates at 1, 2, 3 and 4 years were also similar between groups (97.3%, 86.5%, 78.4% and 78.4%, respectively, in the combined therapy group, and 95.7%, 89.4%, 84.3% and 80.3%, respectively, in the surgical resection group) (p = 0.6321, log-rank test). When compared with surgical resection for the treatment of a single HCC ranging from 2 to 5 cm, RFA combined with TACE shows similar results in terms of recurrence-free and overall survival rates.
    Korean journal of radiology: official journal of the Korean Radiological Society 07/2013; 14(4):626-35. DOI:10.3348/kjr.2013.14.4.626 · 1.57 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Recent studies suggest that the combination of radiofrequency ablation (RFA) and transarterial chemoembolization (TACE) may have a synergistic effect for hepatocellular carcinoma (HCC). The aim of this meta-analysis was to compare the effectiveness of combination of RFA and TACE with that of RFA alone in patients with HCC. Randomized controlled trials and retrospective cohort studies comparing RFA plus TACE with RFA alone for HCC were included into this meta-analysis. Study quality was rated with a standardized scale and the strength of evidence was also rated by using the grading of recommendations assessment, development, and evaluation system (GRADE system). Meta-analyses showed that the combination of RFA and TACE was obviously associated with higher survival rates (odds ratio [OR](1-year) = 2.14, 95 % confidence interval [95 % CI] 1.57-2.91, P < 0.001; OR(3-year) = 1.98, 95 % CI 1.28-3.07, P = 0.001; OR(5-year) = 2.70, 95 % CI 1.42-5.14, P = 0.003). The overall quality of evidence was judged to be low by using the GRADE system. The combination of TACE with RFA can improve the overall survival rate and provides better prognosis for patients with HCC, but more randomized controlled trials using large sample size are needed to provide sufficient evidence.
    Digestive Diseases and Sciences 05/2012; 57(11):3026-31. DOI:10.1007/s10620-012-2212-6 · 2.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: A large number of adrenal tumors are now identified either incidentally or associated with a metastatic workup for cancer. While the vast majority of these lesions are benign, those that prove to be primary or secondary cancers are traditionally treated with surgical resection. A wide variety of alternative, less invasive therapies exist. One of these, thermal ablation, is examined herein. J. Surg. Oncol. 2012; 106:626-631. © 2012 Wiley Periodicals, Inc.
    Journal of Surgical Oncology 10/2012; 106(5):626-31. DOI:10.1002/jso.23191 · 3.24 Impact Factor
Show more